Leerink Partners analyst Geoffrey Porges hasn't changed his tune: He still thinks Gilead should buy Vertex to aid its revenue struggles.
Sarepta’s new CEO pick, Doug Ingram, wins plaudits for commercial savvy, CNS expertise—and sets the stage for more M&A chatter.
Weeks after announcing a €5.32 billion ($5.63 billion) buyout, German generics maker Stada said the deal failed to get shareholder approval.
Could a Pfizer buyout of Bristol-Myers Squibb or AstraZeneca make sense? Sure, one analyst says—but he doesn’t think the drugmaker is interested.
Who could swallow Tesaro and its $7.5B-plus market cap? That was the question just days ago. Now, a pair of M&A-starved pharmas may be trying.
Valeant is in talks to sell its Bausch & Lomb eye surgery business to Carl Zeiss Meditec for potentially $2 billion, Bloomberg reports.
Closely watched maker of cancer drugs Tesaro is up for sale, the WSJ reports, with its new PARP inhibitor Zejula at the heart of a potential deal.
As promised, AstraZeneca is forging ahead with its castoff strategy—and this time, rights to an aged beta blocker are on their way out the door.
Next March, Glaxo gets the option to buy out Novartis’ stake in their consumer health JV—and it's said to be preparing a bid already.
Sanofi Chairman Serge Weinberg says the French drug giant doesn’t need any new purchases.